Novel targeted therapies for advanced esophageal cancer

Authors

  • C.-C. Lin,

    1. Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA;
    2. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan;
    Search for more papers by this author
  • K. P. Papadopoulos

    1. South Texas Accelerated Research Therapeutics, San Antonio, Texas, USA;
    2. Division of Medical Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Search for more papers by this author

Address correspondence to: Kyriakos Papadopoulos, MD, 7979 Wurzbach Road, U415, San Antonio, TX 78229, USA. Email: kyri.papadopoulos@start.stoh.com

Abstract

SUMMARY.  Esophageal cancer is highly aggressive and is the sixth leading cause of cancer death worldwide. Recent advances in multimodality chemoradiotherapy and surgery has improved survival in patients with loco-regional disease, but most patients with advanced stage esophageal cancer have a poor prognosis. Elucidation of the processes involved in esophageal carcinogenesis has identified a number of promising novel targets for therapy. This review focuses on the current status of targeted therapies with potential application to the treatment of advanced esophageal and gastroesophageal junction cancer. The future challenge is to confirm the efficacy of these targeted agents in appropriately selected esophageal cancer patients, and successfully integrate these agents into effective therapies for all stages and subtypes of disease.

Ancillary